Cingulate Inc. provides information for stockholders, potential investors, and financial analysts about its business and financial performance.

Mar 4, 2025 · The data readout includes safety data from two Phase 3 pediatric and adolescent studies – a fixed dose study and a dose optimization study – as well as a food effect study with …

Cingulate is developing ADHD medications capable of achieving precise once-daily dosing using a novel erosion based controlled release technology that provides unrivaled control of drug …

KANSAS CITY, Kan., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc.(NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug …

CTx-1301 utilizes Cingulate’s innovative Precision Timed Release™ (PTR™) drug delivery platform technology to create a breakthrough multi-core formulation of dexmethylphenidate, a …

When did Cingulate become a public company? What was the IPO price? Cingulate became a public company on December 07, 2021 at an initial public offering price of $6 per share. What …

Feb 13, 2024 · About CTx-1301 Cingulate’s lead candidate, CTx-1301, utilizes Cingulate’s proprietary PTR drug delivery platform to create a breakthrough, multi-core formulation of the …

Dec 31, 2024 · The Investor Relations website contains information about Cingulate Inc's business for stockholders, potential investors, and financial analysts.

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved Cingulate Announces Exercise of Warrants for $1.86 Million Gross …

Nov 13, 2023 · Cingulate commenced the pivotal Phase 3 fixed-dose pediatric and adolescent safety and efficacy study in late July 2023 and a Phase 3 pediatric dose-optimization onset …